// App-Quantinova.ai

OR1‐006 : Minimal residual disease assessment in patients with follicular lymphoma treated with obinutuzumab or rituximab as first‐line induction immunochemotherapy in the phase 3 GALLIUM study

Researchers

Presenter

  • C Pott

Principal Investigators

  • E Hoster

  • B Kehden

  • M Unterhalt

  • M Herold

  • R van der Jagt

  • A Janssens

  • M Kneba

  • J Mayer

  • C Pocock

  • N Danesi

  • G Fingerle-Rowson

  • C Harbron

  • K Mundt

  • R Marcus

  • W Hiddemann

Medical Centers

  • University Hospital Schleswig-Holstein, Lubeck, Germany

  • Ludwig-Maximilians-University Hospital Munich,Munich,Alemania

  • HELIOS‐Klinikum, Erfurt, Germany

  • University of Ottawa - Ottawa General Hospital, Ottawa, ON, Canada

  • University Hospital Masaryk University, Brno, Czech Republic

  • East Kent Hospitals, Canterbury, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Kings College London, London, United Kingdom

Locations

  • Germany

  • Canada

  • Belgium

  • Czech Republic

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Peripheral benzodiazepine receptor

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01332968

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved